Special Issue "Advances in Immunotherapeutic Approaches to Diabetes"

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (15 September 2021) | Viewed by 314

Special Issue Editors

1. Nephrology Division, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
2. International Center for T1D, Pediatric Clinical Research Center Fondazione Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Science L. Sacco, University of Milan, 20157 Milan, Italy
3. Division of Endocrinology, ASST Sacco Fatebenefratelli-Sacco, 20157 Milan, Italy
Interests: new immune-based preventive and therapeutic strategies for autoimmune diseases; immunotherapy; type 1 diabetes; transplantation and stem cells to prevent and treat autoimmune diabetes and allograft reject ion
T1D International Center, Pediatric Clinical Research Center Romeo Ed Enrica Invernizzi, Universita di Milano, Milan, Italy
Interests: type 1 diabetes; immunological basis of autoimmune diabetes; stem cells based approach to treat/prevent diabetes and its complications; islet transplantation; immunotherapies; novel immunological pathways to be targeted in type 1 diabetes
T1D International Center, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, Università di Milano, Milano, Italy
Interests: stem cells in type 1 diabetes; autoimmunity and diabetes; regenerative approcahes to treat autoimmune diabetes; immunotherapeutic approaches in type 1 diabetes
Endocrinology Division, ASST Fatebenefratelli-Sacco, Milan, Italy
Interests: type 1 diabetes and its clinical relevance; gestational diabetes; type 2 diabetes and cardiovascular disease; diabetes technology; clinical trials for diabetes
Endocrinology Division, ASST Fatebenefratelli-Sacco, Milan, Italy
Interests: type 1 diabetes and its pathogenesis; clinical trials in diabetes; technology and diabetes; pregnancy and diabetes; beta-cell replacement; type 2 diabetes

Special Issue Information

Dear Colleagues,

Immunotherapy represents a promising therapeutic approach in several disease conditions with increasing clinical applications. In autoimmune diabetes some of the strategies explored to reverse or halt beta-cells destruction are antigen-specific therapies, anti-inflammatory therapies, cell-depleting and stem cell-based therapies. A growing number of evidences suggests a role of innate immune system in triggering and sustaining generalized inflammation also in type 2 diabetes. Moreover, immunomodulation is of paramount importance in islet cell and pancreatic transplantation. Although numerous preclinical works suggested the immune system as a potential useful target in the treatment of diabetes, clinical studies have been only partially successful. This special issue of Metabolites is devoted to providing a complete overview of the rationale for the use of immunotherapy in diabetes and updates on preclinical and clinical studies in the field. We therefore invite review manuscripts as well as original manuscripts dealing with identification of novel immune-based approaches/strategies in diabetes, anti-inflammatory cytokines-based therapy, engineering of biomaterials, autoantigen modulation and other relevant issues.

Prof. Paolo Fiorina
Dr. Francesca D'Addio
Dr. Moufida Ben Nasr
Dr. Ida Pastore
Dr. Andrea Mario Bolla
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • immunotherapy
  • type 1 diabetes
  • type 2 diabetes
  • autoimmune diabetes
  • stem cells therapy
  • inflammation
  • autoimmunity
  • immunomodulation

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop